Literature DB >> 8857068

Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies.

L Aarons1, L P Balant, F Mentre, P L Morselli, M Rowland, J L Steimer, S Vozeh.   

Abstract

An expert meeting to discuss issues relating to the design of population pharmacokinetic/pharmacodynamic (PK/PD) studies was held in Brussels in March 1995, under the auspices of the European Co-operation in Science and Technology (COST), Medicine (B1) programme. The purpose of the meeting was to discuss the experts' experience in designing and performing population PK/PD studies. The topics discussed were current practice, logistical issues, ensuring the accuracy of data, covariate assessment, communication, and protocol design.

Entities:  

Mesh：

Year:  1996        PMID： 8857068     DOI： 10.1007/bf00226323

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  1 in total

1.  Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software.

Authors:  L Aarons; L P Balant; F Mentré; P L Morselli; M Rowland; J L Steimer; S Vozeh
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953
  1 in total
  17 in total

1.  Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.

Authors:  C Chen
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  A pragmatic approach to the design of population pharmacokinetic studies.

Authors:  Amit Roy; Ene I Ette
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 3.  Recommended reading in population pharmacokinetic pharmacodynamics.

Authors:  Peter L Bonate
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.

Authors:  Marylore Chenel; Kayode Ogungbenro; Vincent Duval; Christian Laveille; Roeline Jochemsen; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

5.  Informative study designs to identify true parameter-covariate relationships.

Authors:  Phey Yen Han; Carl M J Kirkpatrick; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-27       Impact factor: 2.745

6.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

Review 7.  Population pharmacokinetics. A regulatory perspective.

Authors:  H Sun; E O Fadiran; C D Jones; L Lesko; S M Huang; K Higgins; C Hu; S Machado; S Maldonado; R Williams; M Hossain; E I Ette
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

8.  Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

Authors:  M O Karlsson; E N Jonsson; C G Wiltse; J R Wade
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

Review 9.  The use of population pharmacokinetics in drug development.

Authors:  S Vozeh; J L Steimer; M Rowland; P Morselli; F Mentre; L P Balant; L Aarons
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

10.  Optimisation of sampling windows design for population pharmacokinetic experiments.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-09-09       Impact factor: 2.745
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.